Table 2 Treatment outcomes for PCP
Patients with prolonged use of a moderate-to-high corticosteroid dose (n = 6) | Patients without prolonged use of a moderate-to-high corticosteroid dose (n = 14) | Total (n = 20) | |
|---|---|---|---|
Treatment regimen, no. (%) | |||
TMP-SMX only | 2 (33) | 7 (50) | 9 (45) |
TMP-SMX prior to intravenous pentamidine | 3 (50) | 1 (7) | 4 (20) |
TMP-SMX prior to atovaquone | 1 (17) | 4 (29) | 5 (25) |
Atovaquone only | 0 | 2 (14) | 2 (10) |
Adjunctive corticosteroids, no. (%) | |||
Not used | 0 | 2 (14) | 2 (10) |
Newly initiated | 0 | 6 (43) | 6 (30) |
Unchanged from baseline dosage | 2 (33) | 0 | 2 (10) |
Increased from baseline dosage | 3 (50) | 6 (43) | 9 (45) |
Decreased from baseline dosage | 1 (17) | 0 | 1 (5) |
Severity of PCP, no. (%) | |||
Mild | 2 (33) | 7 (50) | 9 (45) |
Moderate to severe | 4 (67) | 7 (50) | 11 (55) |
Mortality attributed to PCP, no. (%) | 5 (83) | 3 (21) | 8 (40) |
Thirty-day mortality, no. (%) | 3 (50) | 3 (21) | 6 (30) |